Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GCK | P35557 | 2/20 | 0.42 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.38 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 6/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 4/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.36 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | NOD2 | Q9HC29 | 1/20 | 0.36 |
| ▸ | GRM5 | P41594 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | SCD | O00767 | 1/20 | 0.34 |
| ▸ | DHODH | Q02127 | 2/20 | 0.34 |
| ▸ | MAOB | P27338 | 1/20 | 0.34 |
| ▸ | RRM1 | P23921 | 1/20 | 0.34 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL710843 | 0.90 | GCK (0.41) | GCKMCL1CHEK2DHODHPRMT5 | |
| SCHEMBL709868 | 0.89 | GCK (0.41) | GCKMCL1CHEK2MAPTSCD | |
| SCHEMBL710173 | 0.89 | GCK (0.44) | GCKMCL1CHEK2MAPTKDM4E | |
| SCHEMBL712834 | 0.88 | MAPT (0.40) | GCKMCL1MAPTNPSR1MAPK1 | |
| SCHEMBL710858 | 0.87 | SCD (0.43) | GCKMCL1CHEK2SCD | |
| SCHEMBL710530 | 0.86 | MAPT (0.42) | MCL1CHEK2MAPTNPSR1MAPK1 | |
| SCHEMBL719830 | 0.84 | MCL1 (0.43) | GCKMCL1CHEK2MAPTNPSR1 | |
| SCHEMBL708937 | 0.84 | GRIN1 (0.42) | GCKMAPTNPSR1MAPK1NOD2 | |
| SCHEMBL711041 | 0.84 | GCK (0.43) | GCKMCL1CHEK2MAOBPRMT5 | |
| SCHEMBL711037 | 0.84 | PRMT5 (0.44) | GCKMCL1CHEK2MAPTMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1940837-B1 | IMIDAZOPYRIDINE COMPOUNDS | TAKEDA PHARMACEUTICAL (JP) | 2012-11-07 | — | — | EP | disclosed |
| US-8124617-B2 | Imidazopyridine compounds | TAKEDA SAN DIEGO, INC. (US) | 2012-02-28 | — | — | US | disclosed |
| US-8124617-B2 | Imidazopyridine compounds | TAKEDA SAN DIEGO, INC. (US) | 2012-02-28 | — | — | US | disclosed |
| US-8124617-B2 | Imidazopyridine compounds | TAKEDA SAN DIEGO, INC. (US) | 2012-02-28 | — | — | US | disclosed |
| US-20100069431-A1 | IMIDAZOPYRIDINE COMPOUNDS | TAKEDA SAN DIEGO, INC. | 2010-03-18 | — | — | US | disclosed |
| US-20100069431-A1 | IMIDAZOPYRIDINE COMPOUNDS | TAKEDA SAN DIEGO, INC. | 2010-03-18 | — | — | US | disclosed |
| US-20100069431-A1 | IMIDAZOPYRIDINE COMPOUNDS | TAKEDA SAN DIEGO, INC. | 2010-03-18 | — | — | US | disclosed |
| EP-1940837-A2 | IMIDAZOPYRIDINE COMPOUNDS | Takeda Pharmaceutical Company Limited (JP) | 2008-07-09 | — | — | EP | disclosed |
| WO-2007028135-A2 | IMIDAZOPYRIDINE COMPOUNDS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-03-08 | — | — | WO | disclosed |
| WO-2007028135-A2 | IMIDAZOPYRIDINE COMPOUNDS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-03-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100069431-A1 | IMIDAZOPYRIDINE COMPOUNDS | GCK, GCKR, KHK | GCK 1/4885MCL1 4054/4885CHEK2 1189/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.